ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
Ionizing Radiation Enhances Prognostically Significant Cellular Immunity Programs in the Brain Metastasis Microenvironment.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeBrain metastasis (BM) is a deadly complication of systemic malignancy that has been associated with defective cellular immunity. We sought to characterize the foundational elements and clinical relevance of BM-associated immunosuppression using integrated molecular profiling in primary patient material. EXPERIMENTAL
designRetrospective patient tissue cohorts of breast (n = 153) and lung (n = 153) cancer BM were stratified by histopathologic scoring of tumor-infiltrating lymphocytes (TIL) and clinical outcome, with a large subset of breast cancer samples further analyzed by T-cell receptor sequencing (TCR-seq) and RNA sequencing (RNA-seq). An ongoing clinical trial comparing pre- and postoperative stereotactic radiosurgery (SRS)/stereotactic radiotherapy (SRT) in BM management was then leveraged to dissect radiation-induced immune responses by TCR- and RNA-seq.
resultsPatients with high-grade histopathologic TIL infiltration and enriched TCR diversity demonstrated favorable prognoses in breast and lung cancer BM. Moreover, SRS/SRT treatment enhanced TCR diversity in the BM microenvironment, along with signatures of antigen processing and presentation. Finally, integrated analysis demonstrated that IR seemed to reactivate immune microenvironmental signatures normally suppressed in BM and upregulate immune signaling pathways correlated with favorable outcomes in patients with breast cancer BM.
conclusionsHigh TCR diversity in BM is associated with improved prognosis and highlights therapeutically tractable targets within the immune microenvironment. Moreover, we show in a prospective clinical trial that IR enhances T-cell-mediated immune responses, upregulating antigen presentation and enhancing TCR diversity in BM. These results argue for increased therapeutic investigations of radiation-induced immunomodulatory effects in BM, potentially in association with immune checkpoint inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.